PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsStavudine
Zerit(stavudine)
Zerit (stavudine) is a small molecule pharmaceutical. Stavudine was first approved as Zerit on 1994-06-24. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Stavudine
Tradename
Company
Number
Date
Products
ZERITBristol Myers SquibbN-020412 DISCN1994-06-24
5 products, RLD
ZERITBristol Myers SquibbN-020413 DISCN1996-09-06
1 products, RLD
ZERIT XRBristol Myers SquibbN-021453 DISCN2002-12-31
4 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
stavudineANDA2013-09-30
zeritNew Drug Application2010-08-12
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv infectionsEFO_0000764D015658B20
acquired immunodeficiency syndromeEFO_0000765D000163B20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
— J05AF04: Stavudine
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR07: Stavudine, lamivudine and nevirapine
HCPCS
No data
Clinical
Clinical Trials
174 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B201652362632157
Acquired immunodeficiency syndromeD000163EFO_0000765B2047108734
HivD006678—O98.71226212
TuberculosisD014376EFO_0000774A15-A19132218
LipodystrophyD008060—E88.1—2—428
MeningitisD008581EFO_0000584G03———112
Cryptococcal meningitisD016919EFO_0007228B45.1———112
Disease progressionD018450———1—1—2
Lactic acidosisD000140EFO_1000036E87.20—111—2
Hiv-1D015497—————1—1
Show 13 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—353—314
Communicable diseasesD003141——121—37
MalariaD008288EFO_0001068B54——1——1
Kidney diseasesD007674EFO_0003086N08——1——1
Aids-associated nephropathyD016263EFO_0007313———1——1
DiarrheaD003967—R19.7——1——1
Aids dementia complexD015526EFO_0002608———1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Aids-related complexD000386EFO_0007137B2032——38
Hiv seropositivityD006679———2———2
HypersensitivityD006967EFO_0003785T78.40—1———1
InflammationD007249MP_0001845—11———1
Directly observed therapyD023801———1———1
Metabolic diseasesD008659EFO_0000589E88.9—1———1
Metabolic syndromeD024821EFO_0000195E88.810—1———1
Nutrition disordersD009748EFO_0001069——1———1
Insulin resistanceD007333EFO_0002614E88.819—1———1
HyperlactatemiaD065906———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PregnancyD011247EFO_0002950Z33.11————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis cD006526—B19.2————11
CoinfectionD060085——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameStavudine
INNstavudine
Description
Stavudine is a nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase It has a role as an antimetabolite, an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor and an antiviral agent. It is an organic molecular entity, a nucleoside analogue and a dihydrofuran. It is functionally related to a thymine.
Classification
Small molecule
Drug classantineoplastics; antivirals (zidovudine group) (exception: edoxudine)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O
Identifiers
PDB—
CAS-ID3056-17-5
RxCUI—
ChEMBL IDCHEMBL991
ChEBI ID63581
PubChem CID18283
DrugBankDB00649
UNII IDBO9LE4QFZF (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Stavudine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 10,371 documents
View more details
Safety
Black-box Warning
Black-box warning for: Stavudine, Zerit
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
7,173 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use